Trends in survival for patients with metastatic soft‐tissue sarcoma
- 13 October 2010
- Vol. 117 (5), 1049-1054
- https://doi.org/10.1002/cncr.25538
Abstract
BACKGROUND: The objective of this study was to determine whether the overall survival of patients with metastatic soft tissue sarcoma (STS) has improved over the last 20 years. METHODS: In total, 1024 patients who had synchronous metastatic (SM) STS or metachronous metastatic (MM) STS diagnosed between 1987 and 2006 were included prospectively in the French Sarcoma Group database after central histologic review. Four periods of diagnosis of metastatic disease were defined: P1, from 1987 to 1991 (n = 208); P2, from 1992 to 1996 (n = 287); P3, from 1997 to 2001 (n = 285); and P4, from 2002 to 2006 (n = 244). Patient characteristics were analyzed as prognostic factors by using a Cox model. RESULTS: The proportion of patients with SM, the interval between diagnosis and MM, and the clinical characteristics of the patients were similar across the 4 periods. Although there was no significant difference in the median overall survival (OS) from P1 through P2 (P1, 12.3 months; 95% confidence interval [CI], 9.9‐14.7 months; P2, 11.4 months; 95% CI, 9‐13.9 months), significant improvements were observed in the later periods (P3, 15 months; 95% CI, 11.8‐18.2 months; P4, 18 months; 95% CI, 15.3‐20.7 months; P = .029; log‐rank test). The 2‐year OS rate also increased throughout the study period from 28.1% during P1 to 38.7% during P4. On multivariate analysis, period of diagnosis, age, histologic subtype, time to metastatic recurrence, French Federation of Cancer Centers Sarcoma Group grade, and the number of metastatic sites were independent prognostic factors for OS. CONCLUSIONS: The current analysis revealed that the median OS of patients with metastatic STS had improved by 50% during the last 20 years. These data should be considered in the interpretation of results from ongoing and future STS trials. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsJournal of Clinical Oncology, 2010
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComaAnnals of Oncology, 2010
- Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX StudyJournal of Clinical Oncology, 2008
- Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcomaCancer, 2008
- The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue SarcomasThe Oncologist, 2007
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyThe Lancet Oncology, 2007
- Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard CareThe Oncologist, 2005
- Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entityThe Journal of Pathology, 2004
- Leiomyosarcomas and Most Malignant Fibrous Histiocytomas Share Very Similar Comparative Genomic Hybridization Imbalances: An Analysis of a Series of 27 LeiomyosarcomasLaboratory Investigation, 2001
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984